Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Candesartan Cilexetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.70 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | PPARG | P37231 | 2/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.70 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | MLNR | O43193 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candesartan Cilexetil SCHEMBL474557 | 0.95 | AGTR2 (0.76) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Candesartan Cilexetil SCHEMBL1021483 | 0.94 | NAE1 (0.79) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Candesartan Cilexetil SCHEMBL16949997 | 0.94 | NAE1 (0.79) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Candesartan Cilexetil SCHEMBL3968703 | 0.94 | NAE1 (0.79) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Candesartan Cilexetil SCHEMBL40831 | 0.94 | NAE1 (0.79) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Candesartan Cilexetil SCHEMBL6515280 | 0.93 | NAE1 (0.78) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Candesartan Cilexetil SCHEMBL1775074 | 0.91 | NAE1 (0.75) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Candesartan Cilexetil SCHEMBL15544662 | 0.89 | NAE1 (0.71) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL1459137 | 0.89 | AGTR1 (0.72) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL7299885 | 0.89 | NAE1 (0.69) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473160-A1 | DELIVERY OF THERAPEUTIC AGENTS USING OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS CARRIERS | Northwestern University (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028850-A1 | DELIVERY OF THERAPEUTIC AGENTS USING OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS CARRIERS | NORTHWESTERN UNIVERSITY (US) | 2011-03-10 | — | — | WO | disclosed |